相关实验视频

Updated: Jul 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

在第一/第二代EGFR-TKI失败后,T790M阴性NSCLC中的第三代EGFR-TKI:回顾性研究

Zhen Cheng1,2, Jiali Dong1, Huihao Lu1

  • 1Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.

Cancer medicine
|December 16, 2025
PubMed
概括

第三代EGFR-TKIs显著提高了T790M阴性非小细胞肺癌患者的无进展生存率,这些患者对早期EGFR-TKIs有抗性. 这为这个患者群体提供了更好的治疗选择.

关键词:
在T790MM中.皮肤上生长因子受体.非小细胞肺癌的肺癌.电阻的阻力可以氨酸激酶抑制剂 氨酸激酶抑制剂

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...